ImmunoGen, Inc. Announces Presentation At American Society of Hematology Of Encouraging Findings With HuN901-DM1 For The Treatment Of Multiple Myeloma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) announced the presentation today of encouraging initial findings from a Phase I study evaluating the Company’s huN901-DM1 Tumor-Activated Prodrug (TAP) compound for the treatment of multiple myeloma at the annual meeting of the American Society of Hematology (ASH) in Orlando, FL. These initial findings show evidence of anticancer activity among the patients receiving the higher of the two huN901-DM1 dose levels evaluated to date. ImmunoGen also announced progress with the TAP compound, AVE9633, which is in development by sanofi-aventis for the treatment of acute myeloid leukemia (AML). The Company’s TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells.

Back to news